Edition:
India

Almirall To Make Decision Regarding Exercise Of Its Lebrikizumab Option By Mid-Year


Monday, 3 Jun 2019 

June 3 (Reuters) - Almirall SA ::TO MAKE DECISION REGARDING EXERCISE OF OPTION TO EXCLUSIVELY LICENSE RIGHTS TO DEVELOP AND COMMERCIALIZE LEBRIKIZUMAB IN EUROPE BY MID-YEAR.IF ALMIRALL ELECTS TO EXERCISE ITS OPTION, COMPANY WILL PAY DERMIRA AN OPTION EXERCISE FEE OF $50 MILLION.